We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ApoCell to Conduct Studies in Support of Pfizer Cancer Drug Trial
News

ApoCell to Conduct Studies in Support of Pfizer Cancer Drug Trial

ApoCell to Conduct Studies in Support of Pfizer Cancer Drug Trial
News

ApoCell to Conduct Studies in Support of Pfizer Cancer Drug Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ApoCell to Conduct Studies in Support of Pfizer Cancer Drug Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ApoCell Inc. has been engaged by Pfizer, Inc. to support a Phase 1 clinical trial being conducted in three sites in the U.S. and abroad.

ApoCell will use its target expression profile (TEP™) technology along with immunohistochemistry to generate data to select those patients most likely to benefit from the drug and will then process patient samples to quantify the pharmacodynamic activity of the new drug.

A new paradigm in clinical trial design: Selecting patients for clinical trials based on predicting drug response can help bring cancer drugs to market sooner. Many new cancer drugs target specific parts of cancer cells or related biochemical processes. Although they are very powerful and much better tolerated, scientists have found that individual response to these agents can vary widely. A diagnostic test that indicates whether a patient will respond to treatment is very promising.

Diagnostic biomarkers – transforming biology into information: Cancer biomarkers are the biological “neon signs” that advertise the presence or absence of cancer cells. A very complex disorder, cancer manifests itself in many ways. Cancer biomarkers must therefore distinguish and detect the presence or future presence of a specific malignancy with a high degree of accuracy.

Dr. Darren Davis, ApoCell’s CEO, comments, “We have isolated and measured cancer biomarker intensity for ten years using advanced technologies such as lasers. We can detect and measure very small changes in protein expression and have shown that protein biomarker expression correlates with clinical outcome and can be used to predict the efficacy of cancer drug therapies. We are very excited to work with Pfizer on this project.”

Advertisement